Quick Read Moderna (MRNA) generated $1.944B in full-year 2025 revenue (down 39.2% YoY) with negative $2.822B net loss and ...

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...

The COVID pandemic ushered mRNA vaccines into the spotlight, and the technology has even greater potential. Here’s what to ...

There's renewed debate on the future of mRNA vaccines, and Johns Hopkins researchers want to clear up some misconceptions around the shots.

When people talk about transformative technologies today, the conversation usually moves quickly to artificial intelligence, ...

Scientists are making rapid progress toward a long-awaited goal that could help to reshape cancer care: mRNA cancer vaccines ...

The biotech industry needs to stop waiting for a rebound. The pandemic changed everything, though not in the ways most people ...

An Australian tech entrepreneur has helped create what appears to be a made-to-measure cancer vaccine for his dog, Rosie, ...

RNA cancer vaccines have the potential to significantly boost the immune system’s ability to fight and eliminate tumors.

Few corporate cautionary tales are as vivid as the rise and fall of Moderna Inc. During the pandemic, the company's mRNA vaccine was approved and distributed in record time, saving millions of lives ...

Combined with the administration’s erratic regulation and policymaking, it threatens to undo the salutary ecosystem that made ...

VetClaw by OpenVet introduces species aware, safety-first clinical workflows designed to help advance the future of ...